ABIONYX PHARMA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.248 EUR | 0.00% |
|
+0.48% | -3.11% |
| Mar. 14 | Abionyx Pharma: to benefit from a 1ME grant from Bpifrance | CF |
| Mar. 11 | Abionyx: reduced net loss in 2023 | CF |
Quotes 5-day view
Real-time Euronext Paris| 2024-05-29 | 2024-05-30 | 2024-05-31 | 2024-06-03 | 2024-06-04 | |
|---|---|---|---|---|---|
| Last | 1.18 € | 1.18 € | 1.25 € | 1.248 € | 1.248 € |
| Volume | 163 504 | 38 656 | 97 319 | 51 609 | 17 131 |
| Change | -4.99% | 0.00% | +5.93% | -0.16% | 0.00% |
| Opening | 1.25 | 1.19 | 1.19 | 1.25 | 1.256 |
| High | 1.28 | 1.20 | 1.26 | 1.25 | 1.256 |
| Low | 1.11 | 1.17 | 1.16 | 1.21 | 1.23 |
Performance
| 1 day | -1.44% | ||
| 1 week | -0.97% | ||
| Current month | -1.60% | ||
| 1 month | +15.82% | ||
| 3 months | +14.95% | ||
| 6 months | -6.53% | ||
| Current year | -4.50% | ||
| 1 year | -6.68% | ||
| 3 years | -3.61% | ||
| 5 years | +214.98% |
Volumes
marketsDaily volume
9 145
Estimated daily volume
50 353
Avg. Volume 20 sessions
106 288
Daily volume ratio
0.47
Avg. Volume 20 sessions
132 647.42
Avg. Volume 20 sessions USD
144 458.35
Record volume 1
14 327 720
Record volume 2
10 533 110
Record volume 3
7 586 921
Capital turnover ratio
0.00
Float rotation
0.00
Basic data
Capitalization (EUR)
40 176 189
Capitalization (USD)
43 753 477
Net sales (EUR)
4 600 000
Net sales (USD)
5 009 584
Number of employees
63
Sales / Employee (EUR)
73 016
Sales / Employee (USD)
79 517
Free-Float
68.01 %
Free-Float capitalization (EUR)
27 540 410
Free-Float capitalization (USD)
29 992 608
Average Daily Capital Traded
0.33%
Highs and lows
1 week
1.11
1.28
1 month
1.011.31
Current year
0.911.32
1 year
0.911.47
3 years
0.903.57
5 years
0.203.57
10 years
0.2014.44
Indicators
Moving average 5 days
1.22
Moving average 20 days
1.14
Moving average 50 days
1.08
Moving average 100 days
1.12
Price spread / (MMA5)
-2.24%
Price spread / (MMA20)
-8.41%
Price spread / (MMA50)
-13.24%
Price spread / (MMA100)
-10.31%
STIM
RSI 9 days
63.25
RSI 14 days
61.77
Sector Comparison - Bio Therapeutic Drugs
| Name | Change | 5d. change | 1st Jan change | 1-year change | Capi. | |
|---|---|---|---|---|---|---|
| 0.00% | -0.97% | -4.50% | -6.68% | 43.75M | ||
| +3.26% | +2.90% | +15.55% | +40.87% | 121B | ||
| +0.95% | +0.45% | +12.66% | +33.72% | 107B | ||
| +2.26% | +6.11% | -2.53% | -4.86% | 24.82B | ||
| -0.14% | +2.72% | +0.99% | -7.32% | 22.48B | ||
| -0.15% | +0.88% | -9.44% | -28.86% | 18.32B | ||
| -0.26% | -0.99% | -42.28% | -38.09% | 16.33B | ||
| -1.75% | -4.24% | -18.92% | -35.68% | 15.31B | ||
| +3.33% | +0.37% | +6.19% | +51.56% | 14.08B | ||
| -4.28% | +0.62% | +28.83% | -0.74% | 11.74B | ||
| +1.62% | +154.27% | +80.51% | +186.28% | 9.02B | ||
| +0.16% | +3.76% | +7.43% | +48.20% | 7.76B | ||
| +2.68% | +4.93% | +14.89% | +42.22% | 7.85B | ||
| -0.27% | -1.69% | -4.17% | +21.72% | 7.4B | ||
| +0.05% | -3.33% | -33.47% | -36.84% | 7.3B | ||
| +0.02% | -0.76% | +234.61% | +179.49% | 6.87B | ||
| Average | +0.35% | +10.50% | +17.90% | +27.81% | ||
| Weighted average by Cap. | +1.37% | +4.87% | +11.84% | +27.18% |
Historical data
| Date | Opening | High | Low | End-of-day | Volume |
|---|
Last transactions
c33ebbb83e57df588ee5e146.dynlbTLX8kQYapJdpBKBJFtFlkRdul4cPG8UCS0HpNc.Q0zTPnbjxnEvWeg70mXEaXYoxn0f9C5aYyMscUtw4PoGWdwsc5qGM38Qpg
| Date | Price | Volume | Daily volume |
|---|---|---|---|
| 04:33:32 am | 1.248 | 600 | 9,145 |
| 04:15:53 am | 1.23 | 601 | 8,545 |
| 04:15:53 am | 1.24 | 65 | 7,944 |
| 04:10:10 am | 1.252 | 100 | 7,879 |
| 03:11:44 am | 1.248 | 60 | 7,779 |
| 03:09:26 am | 1.254 | 82 | 7,719 |
| 03:07:54 am | 1.254 | 500 | 7,637 |
| 03:01:03 am | 1.25 | 100 | 7,137 |
| 03:00:28 am | 1.256 | 1 | 7,037 |
| 03:00:28 am | 1.256 | 69 | 7,036 |
Monthly variations
Annual change
| 2024 | -3.11% | ||
| 2023 | -25.20% | ||
| 2022 | -29.57% | ||
| 2021 | +147.22% | ||
| 2020 | +193.47% | ||
| 2019 | -31.22% | ||
| 2018 | -74.35% | ||
| 2017 | -77.92% | ||
| 2016 | -32.00% | ||
| 2015 | +3.16% |
- Stock Market
- Equities
- ABNX Stock
- Quotes ABIONYX Pharma
